KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Receivables (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Receivables readings, the most recent being $3.4 billion for Q1 2026.

  • On a quarterly basis, Receivables changed 0.27% to $3.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.4 billion, a 0.27% change, with the full-year FY2025 number at $3.7 billion, up 21.25% from a year prior.
  • Receivables hit $3.4 billion in Q1 2026 for Teva Pharmaceutical Industries, down from $3.7 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $4.5 billion in Q2 2022 to a low of $3.1 billion in Q4 2024.
  • Median Receivables over the past 5 years was $3.5 billion (2023), compared with a mean of $3.6 billion.
  • Biggest five-year swings in Receivables: dropped 20.85% in 2023 and later increased 21.25% in 2025.
  • Teva Pharmaceutical Industries' Receivables stood at $3.7 billion in 2022, then fell by 7.79% to $3.4 billion in 2023, then decreased by 10.24% to $3.1 billion in 2024, then rose by 21.25% to $3.7 billion in 2025, then dropped by 8.52% to $3.4 billion in 2026.
  • The last three reported values for Receivables were $3.4 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.8 billion (Q3 2025) per Business Quant data.